Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel diseaseJeremy Liu Chen Kiow, Greg Rosenfeld, Harjot Bedi et al.|World Journal of Gastroenterology|2024Cited by 9